Asst Vice President for Program Innovation, Asst Director of Distance and Global Initiatives, Associate Professor, Bio5 Institute, Nutritional Sciences
Randy Burd, Ph.D. is the Assistant Vice President for Program Innovation in the Office of Global Initiatives. He also serves as the Director of Distance and Global Initiatives in the College of Agriculture and Life Sciences, where he holds a faculty appointment as an Associate Professor of Nutritional Sciences. His role in these linked positions is to lead the expansion of new programs and initiatives to increase global presence. He also has extensive expertise in technology and distance education and in developing international research and academic programs.
Dr. Burd received his Ph.D. in Molecular and Cellular Biophysics in 1998 from the Roswell Park Cancer Institute in Buffalo, New York. In 2002 he was appointed the director of Pre-Clinical Therapeutics at Thomas Jefferson University. In 2005 he was recruited to the University of Arizona to establish a Nutrigenomics program to identify new bioactive food compounds that could be developed into pharmaceuticals. In 2012 he assumed the role of Assistant Vice President for Program Innovation in Global Initiatives. His current research efforts focus on bioactive food compounds and he also publishes in the areas of technology and innovation. He currently teaches a course in Nutrigenomics. His research and education programs have been funded through various sources including international, federal, state, foundation and industrial sources.
Current research interests in our laboratory focus on improving tumor radiation response through the use of biological response modifiers that alter tumor cell function, metabolism, cytokine stimulation and prostaglandin production, and affect aspects of tumor development, growth and treatment response. These include pharmaceutical drugs that are designed to specifically target tumors, bioactive nutritional components such as bioflavonoids, and compounds that regulate tumor glucose metabolism.
1. Mars MM and Burd R. Impact over Profits: Toward a Social Entrepreneurship Model for University Technology Transfer. J Entrepreneurship & Organization Mgmt. 2013, In Press.
2. The promise of digital (mobile) health in cancer prevention and treatment. Panayi ND, Mars MM, Burd R. Future Oncol 2013;9(5):613-7.
3. Collection and visualization of dietary behavior and reasons for eating using twitter. Hingle M, Yoon D, Fowler J, Kobourov S, Schneider ML, Falk D, Burd R. J Med Internet Res 2013;24;15(6):e125.
4. Mendoza EE, Pocceschi M, Kong X, Caro J, Limesand KH, Leeper DB, Burd R. Control of Glycolytic Flux by AMP-Activated Protein Kinase in Tumor Cells Adapted to Low pH, Translational Oncology, 2012;5(3):208-216.
5. Martin KL, Hill GA, Klein RR, Arnett DG, Burd R, Limesand KH. Prevention of radiation-induced salivary gland dysfunction utilizing a CDK inhibitor in a mouse model PLoS One 2012;7(12).
6. Mendoza EE, Burd R. Quercetin as a systemic chemopreventative agent: structural and functional mechanisms. Mini Rev Med Chem. 2011 Dec 1;11(14):1216-21.
7. Mitchell GC, Fillinger JL, Sittadjody S, Avila JL, Burd R, Limesand KH. IGF1 activates cell cycle arrest following irradiation by reducing binding of ΔNp63 to the p21 promoter. Cell Death Dis. 2010;1:e50.
8. Vargas AJ, Sittadjody S, Thangasamy T, Mendoza EE, Limesand KH, Burd R. Exploiting tyrosinase expression and activity in melanocytic tumors: quercetin and the central role of p53. Integr Cancer Ther. 2011 Dec;10(4):328-40. Epub 2010 Dec 31.
9. Victory K, Burd R, Fribley A, Sittadjody S, Arnett D, Klein RR, Limesand KH. Head and neck tumor cell radiation response occurs in the presence of IGF1. J Dent Res. 2011 Mar;90(3):347-52.
10. Mitchell G, Fillinger J, Sittadjody S, Avila J, Burd R, Limesand K. IGF1 activates cell cycle arrest following irradiation by reducing binding of ΔNp63 to the p21 promoter. Cell Death Dis. 2010 Jun 10;2010(1):e50.
11. Grundmann O, Fillinger JL, Victory KR, Burd R, Limesand KH. Restoration of radiation therapy-induced salivary gland dysfunction by post therapy IGF-1 administration. BMC Cancer. 2010 Aug 10;10:417.
12. Vargas AJ, Burd R. Hormesis and synergy: pathways and mechanisms of quercetin in cancer prevention and management. Nutr Rev. 2010 Jul;68(7):418-28.
13. Thangasamy T, Sittadjody S, Mitchell GC, Mendoza EE, Radhakrishnan VM, Limesand KH, Burd R. Quercetin abrogates chemoresistance in melanoma cells by modulating deltaNp73. BMC Cancer. 2010 Jun 11;10:282.
Limesand K. H., Hingle M.